Scholarlink

<p><i>Polygonum plebeium</i> R. Br. (Polygonaceae), commonly known as small knotweed, is traditionally used in South Asia to treat intestinal disorders, pneumonia, and menstrual ailments. The present study systematically evaluated its Antidiabetic potential through integrated phytochemical, in vitro, in vivo, and in silico approaches. Aerial parts were sequentially extracted using solvents of increasing polarity, and the ethanol extract was analyzed by GC–MS, identifying 11 phytoconstituents. Oleic acid (24.06%) and pentadecanoic acid ethyl ester (21.99%) were major compounds. In vitro Antidiabetic activity demonstrated significant enzyme inhibition, with IC₅₀ values of 95.06 ± 0.35&#xa0;µg/mL for α-amylase and 90.32 ± 0.64&#xa0;µg/mL for α-glucosidase. In vivo studies included oral glucose tolerance test (OGTT), acute and chronic antihyperglycemic evaluations, and streptozotocin-induced diabetic rat models. At 400&#xa0;mg/kg, the extract reduced blood glucose by 30.52% after 3&#xa0;h in OGTT. Acute treatment produced a 55.74 ± 3.47% reduction at 8&#xa0;h, while 30-day administration resulted in a 59.79 ± 1.07% decrease. Significant improvements were observed in liver enzymes, HbA1c, total protein, and lipid profile. Histopathological analysis revealed regeneration of pancreatic islets and restoration of liver and kidney architecture. Network pharmacology identified PPARα as a key diabetic target, and GC–MS-identified major compounds showed higher docking affinity than metformin. In conclusion, <i>P. plebeium</i> exhibited noticeable Antidiabetic potential, warranting further and justify further investigation for therapeutic investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Protective and antidiabetic effects of Polygonum plebeium R.Br. in STZ-induced diabetic rats

  • 期刊论文

  • 发表日期：

    2026年6月23日

查看全文
  • Sarojini Nayak,
  • Druga Madhab Kar,
  • N Saroj Kumar Choudhury,
  • Smrutiranjan Dash

摘要

Polygonum plebeium R. Br. (Polygonaceae), commonly known as small knotweed, is traditionally used in South Asia to treat intestinal disorders, pneumonia, and menstrual ailments. The present study systematically evaluated its Antidiabetic potential through integrated phytochemical, in vitro, in vivo, and in silico approaches. Aerial parts were sequentially extracted using solvents of increasing polarity, and the ethanol extract was analyzed by GC–MS, identifying 11 phytoconstituents. Oleic acid (24.06%) and pentadecanoic acid ethyl ester (21.99%) were major compounds. In vitro Antidiabetic activity demonstrated significant enzyme inhibition, with IC₅₀ values of 95.06 ± 0.35 µg/mL for α-amylase and 90.32 ± 0.64 µg/mL for α-glucosidase. In vivo studies included oral glucose tolerance test (OGTT), acute and chronic antihyperglycemic evaluations, and streptozotocin-induced diabetic rat models. At 400 mg/kg, the extract reduced blood glucose by 30.52% after 3 h in OGTT. Acute treatment produced a 55.74 ± 3.47% reduction at 8 h, while 30-day administration resulted in a 59.79 ± 1.07% decrease. Significant improvements were observed in liver enzymes, HbA1c, total protein, and lipid profile. Histopathological analysis revealed regeneration of pancreatic islets and restoration of liver and kidney architecture. Network pharmacology identified PPARα as a key diabetic target, and GC–MS-identified major compounds showed higher docking affinity than metformin. In conclusion, P. plebeium exhibited noticeable Antidiabetic potential, warranting further and justify further investigation for therapeutic investigation.